However, considering that diabetes induces endothelial dysfunction and reduces NO bioavailability, administration of anti-VEGF antibodies in the diabetic condition is likely to result in proteinuria and renal dysfunction. The gene discussed is VEGFA; the disease is diabetes mellitus.